PE20040538A1 - Polimorfos inhibidores de xantina fosfodiesterasa v - Google Patents

Polimorfos inhibidores de xantina fosfodiesterasa v

Info

Publication number
PE20040538A1
PE20040538A1 PE2003000535A PE2003000535A PE20040538A1 PE 20040538 A1 PE20040538 A1 PE 20040538A1 PE 2003000535 A PE2003000535 A PE 2003000535A PE 2003000535 A PE2003000535 A PE 2003000535A PE 20040538 A1 PE20040538 A1 PE 20040538A1
Authority
PE
Peru
Prior art keywords
degrees
polymorph
polymorphes
inhibiting
refers
Prior art date
Application number
PE2003000535A
Other languages
English (en)
Inventor
Craig D Boyle
Buchholtz
Vilas H Dahnukar
Kevin Klopfer
Fucheng Zhang
Cecilia A Orr
Jeffrey M Skell
Ilia A Zavialov
Hoa N Nguyen
Original Assignee
Schering Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Corp filed Critical Schering Corp
Publication of PE20040538A1 publication Critical patent/PE20040538A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
    • C07D473/04—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pulmonology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Vascular Medicine (AREA)
  • Emergency Medicine (AREA)
  • Gynecology & Obstetrics (AREA)
  • Transplantation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

SE REFIERE AL POLIMORFO CRISTALINO DE 1-ETIL-3,7-DIHIDRO-8-[(1R,2R)-(HIDROXICICLOPENTIL)AMINO]-3-(2-HIDROXIETIL)-7-[(3-BROMO-4-METOXIFENIL)METIL]-1H-PURINA-2,6-DIONA EN FORMA 1 Y 2 CUYOS PATRONES DE DIFRACCION DE POLVO POR RAYOS X TIENE UBICACIONES DE PICOS CARATERISTICOS DE 7,3; 9,2; 20,2 GRADOS 2q +/- 0,5 GRADOS 2q Y DE 8,1; 11,3; 17,2 Y 22,2 GRADOS 2q +/- 0,5 GRADOS 2q RESPECTIVAMENTE. DICHO POLIMORFO SE PREPARA POR CRISTALIZACION DE DICHO POLIMORFO EN UN SOLVENTE ESENCIALMENTE NO ACUOSO ORGANICO SELECCIONADO DE ALCOHOLES, NITRILOS, ESTERES, CETONAS Y MEZCLAS DE LOS MISMOS. SE REFIERE TAMBIEN A UNA COMPOSICION FARMACEUTICA RELACIONADA, QUE ES UTIL PARA TRATAR UNA VARIEDAD DE TRASTORNOS FISIOLOGICOS, TALES COMO LA DISFUNCION ERECTIL
PE2003000535A 2002-05-31 2003-05-30 Polimorfos inhibidores de xantina fosfodiesterasa v PE20040538A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US38448402P 2002-05-31 2002-05-31

Publications (1)

Publication Number Publication Date
PE20040538A1 true PE20040538A1 (es) 2004-08-30

Family

ID=29712042

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2003000535A PE20040538A1 (es) 2002-05-31 2003-05-30 Polimorfos inhibidores de xantina fosfodiesterasa v

Country Status (16)

Country Link
US (1) US7192962B2 (es)
EP (1) EP1509524B1 (es)
JP (1) JP2005529933A (es)
CN (1) CN100384844C (es)
AR (1) AR040233A1 (es)
AT (1) ATE390425T1 (es)
AU (1) AU2003249658A1 (es)
CA (1) CA2486174A1 (es)
DE (1) DE60319980T2 (es)
ES (1) ES2299720T3 (es)
HK (1) HK1068140A1 (es)
MX (1) MXPA04011865A (es)
PE (1) PE20040538A1 (es)
TW (1) TW200404802A (es)
WO (1) WO2003101991A1 (es)
ZA (1) ZA200409644B (es)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6821978B2 (en) * 2000-09-19 2004-11-23 Schering Corporation Xanthine phosphodiesterase V inhibitors
KR100897218B1 (ko) * 2001-03-27 2009-05-14 다이닛본 스미토모 세이야꾸 가부시끼가이샤 결정성 이속사졸 유도체 및 그의 약학 제제
DK1509525T5 (da) * 2002-05-31 2007-07-30 Schering Corp Fremgangsmåde til fremstilling af xanthin-phosphodiesterase V-inhibitorer og præcursorer derfor
MXPA06001195A (es) 2003-07-31 2006-04-11 Schering Corp Metabolito de inhibidor de xantina fosfodiesterasa 5 y derivados del mismo utiles para el tratamiento de la disfuncion erectil.
AU2004292991A1 (en) * 2003-11-21 2005-06-09 Schering Corporation Phosphodiesterase v inhibitor formulations
JP4880591B2 (ja) 2004-06-04 2012-02-22 テバ ファーマシューティカル インダストリーズ リミティド イルベサルタンを含む医薬組成物
CN101102775A (zh) * 2004-11-18 2008-01-09 先灵公司 采用pdev抑制剂治疗充血性心衰的方法
US20070004745A1 (en) * 2005-03-25 2007-01-04 Schering-Plough Corporation Methods of treating benign prostatic hyperplasia or lower urinary tract symptoms by using PDE 5 inhibitors
PT1883397E (pt) * 2005-05-17 2010-02-23 Actelion Pharmaceuticals Ltd Comprimido dispersível de bosentano
JP2008546786A (ja) * 2005-06-23 2008-12-25 シェーリング コーポレイション Ｐｄｅ５インヒビターの迅速吸収性経口処方物
US9012454B2 (en) 2005-12-09 2015-04-21 Mayo Foundation For Medical Education And Research Sexual dysfunction
WO2008139574A1 (ja) * 2007-04-27 2008-11-20 Ajinomoto Co., Inc. ラクタム化合物の結晶形およびその製造方法
JOP20190144A1 (ar) 2016-12-16 2019-06-16 Janssen Pharmaceutica Nv إيميدازو بيرولو بيريدين كمثبطات لعائلة jak الخاصة بإنزيمات الكيناز
TW202016110A (zh) 2018-06-15 2020-05-01 比利時商健生藥品公司 Ｊａｋ激酶家族之小分子抑制劑

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9301192D0 (en) * 1993-06-09 1993-06-09 Trott Francis W Flower shaped mechanised table
TW403740B (en) * 1997-06-10 2000-09-01 Novartis Ag Novel crystal modifications of the compound 1-(2,6-difluorobenzyl)-1H-1,2,3-triazole-4-carboxamide
IL133357A (en) * 1997-07-02 2003-12-10 Merck & Co Inc Polymorphic form of the tachykinin receptor antagonist 2-(r)-(1-(r)- (3,5-bis(trifluoromethyl) phenyl) ethoxy)-3-(s)-(4-fluoro) phenyl-4- (3-5(-oxo-1h, 4h-1,2,4-triazolo) methylmorpholine
AU743515B2 (en) * 1997-08-27 2002-01-24 Elanco Tiergesundheit Ag Dicyclanil polymorphs and hydrates and their preparation
MA24682A1 (fr) * 1997-10-23 1999-07-01 Smithkline Beecham Corp Formes polymorphes nouvelles de cipamfylline, procede pour leur preparation et compositions les contenant
FR2779726B1 (fr) * 1998-06-15 2001-05-18 Sanofi Sa Forme polymorphe de l'hydrogenosulfate de clopidogrel
US6821978B2 (en) * 2000-09-19 2004-11-23 Schering Corporation Xanthine phosphodiesterase V inhibitors
DK1509525T5 (da) * 2002-05-31 2007-07-30 Schering Corp Fremgangsmåde til fremstilling af xanthin-phosphodiesterase V-inhibitorer og præcursorer derfor

Also Published As

Publication number Publication date
CA2486174A1 (en) 2003-12-11
EP1509524A1 (en) 2005-03-02
AR040233A1 (es) 2005-03-23
HK1068140A1 (en) 2005-04-22
WO2003101991A1 (en) 2003-12-11
ATE390425T1 (de) 2008-04-15
US7192962B2 (en) 2007-03-20
TW200404802A (en) 2004-04-01
CN1656097A (zh) 2005-08-17
ZA200409644B (en) 2005-10-18
CN100384844C (zh) 2008-04-30
EP1509524B1 (en) 2008-03-26
AU2003249658A1 (en) 2003-12-19
DE60319980T2 (de) 2009-04-16
US20030232845A1 (en) 2003-12-18
MXPA04011865A (es) 2005-03-31
ES2299720T3 (es) 2008-06-01
DE60319980D1 (en) 2008-05-08
JP2005529933A (ja) 2005-10-06

Similar Documents

Publication Publication Date Title
PE20040538A1 (es) Polimorfos inhibidores de xantina fosfodiesterasa v
ES2572980T3 (es) Combinación de inhibidores de la proteasa del VHC con un tensioactivo
ES2900815T3 (es) Compuestos y métodos para inducir la condrogénesis
PE20061319A1 (es) Cristales formados de clorhidrato de {[(2r)-7-(2,6-diclorofenil)-5-fluoro-2-3-dihidro-1-benzofurano-2-il]metil}amina
AR082825A2 (es) Inhibidores heterociclicos nitrogenados de mek, composiciones farmaceuticas que los contienen, metodos para prepararlos y uso de los mismos para el tratamiento de trastornos hiperproliferativos o inflamatorios
BRPI0514750A (pt) derivados amida de 7-amino-3-fenil-diidropirimido[4, 5-d]pirimidinonas, sua fabricação e uso como inibidores de proteìna cinase
UY28374A1 (es) Agentes terapéuticos
PE20070218A1 (es) COMPUESTOS DE CICLOALQUILO AMINO-HIDANTOINA Y USO DE ESTOS PARA LA MODULACION DE ß-SECRETASA
EA200701224A1 (ru) Способ борьбы с грибковыми заболеваниями бобовых культур
AR045595A1 (es) Composiciones utiles como inhibidores de proteinas quinasas
AR051735A1 (es) Inhibidores pirrolicos de la proteina quinasa erk, sintesis e intermediarios de los mismos.
AR053748A1 (es) Entidades quimicas, composiciones y metodos.
CO5580767A2 (es) Compuestos de indazol y composiciones farmaceuticas para inhibir proteinquinasas y procedimientos para su uso
UY28144A1 (es) Agentes terapéuticos
BRPI0413232B8 (pt) composto tendo atividade inibitória contra transportador dependente de sódio, composição farmacêutica compreendendo o composto, uso do composto na preparação de um medicamento e processo para a preparação do composto
EA200100971A1 (ru) Новые соединения и композиции в качестве ингибиторов протеазы
AR024060A1 (es) Nuevos compuestos farmaceuticamente activos
AR071236A1 (es) Inhibidores ciclicos de la 11beta-hidroxiesteroide deshidrogenasa 1
AR068528A1 (es) Formas solidas de n-(5-tert-butil-isoxazol-3-il)-n'-(4(7-(2-morfolin-4-il-etoxi) imidazol(2,1-b)(1,3)benzotiazol-2-il)fenil)urea, composiciones con las mismas y usos de los mismos
CO5690551A2 (es) Derivados de tetrazol y metodos para el tratamiento con los mismos de trastornos relacionados con el metabolismo
PE20020566A1 (es) DERIVADOS DE FENILACETAMIDO-PIRAZOLES COMO INHIBIDORES DE LA cdk/CICLINA QUINASA
UY27039A1 (es) Formas de sal de amida de acido 3-(4-bromo-2,6-difluoro-benciloxi)-5-(3-(pirrolidin-1-ilbutil)ureido)isotiazol-4-carboxilico y métodos de producción
AR069098A1 (es) Inhibidores macrociclicos de la ns3 serina proteasa del virus de la hepatitis c
DK1268418T3 (da) Farmaceutisk aktive pyrrolidinderivater som Bax-inhibitorer
CL2011003302A1 (es) Compuestos derivados de amida del acido alquil-sulfonico; composicion farmaceutica; uso de los compuestos como moduladores de la disfuncion de glutamato para prevenir o tratar trastornos neurologicos y psiquiatricos como esquizofrenia, enfermedad de alzheimer, trastornos de deficit de atencion/hiperactividad, perdida de audicion, entre otros.

Legal Events

Date Code Title Description
FC Refusal